Market Insights

Unsupported drug price increases have cost the U.S. health system $1.67 billion.

Morgan Stanley offers steps to take to encourage more asset owners to realize the benefits of a diversity-based investment strategy.

Private insurers say they need more evidence that the treatment actually slows the rate at which Alzheimer's patients deteriorate.

Take a look at how have FSAs, HSAs, HRAs and other consumer-directed health accounts have fared over the past decade.

Whether a federal program is included in the reconciliation package is questionable, but states' efforts continue to soldier forward.

Even states that are generally considered high-performers in terms of overall health could see wide disparities.